AKT1 and neoplasm: In the EGFR-mutant cell lines, the variable inhibitors of PI3K-AKT and MAPK-ERK presented variable antitumor activity (Figures 5F, H, J), indicating that the ability of TKIs to eliminate tumor cells accounted for the inhibitor of survival signaling, including PI3K-AKT and MAPK-ERK.